Baseline characteristics in stroke patients with atrial fibrillation: Clinical trials versus clinical practice

BMC Research Notes

Volumn 8, Issue 1, 2015, Pages

  Tanislav, Christian ^a   Milde, Sonja ^b   Schwartzkopff, Sabine ^c   Misselwitz, Björn ^d   Sieweke, Nicole ^a   Kaps, Manfred ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b DRESDEN INTERNATIONAL UNIVERSITY   (Germany)

^c AOK Division of the Federal State of Hesse   (Germany)

^d Geschäftsstelle Qualitätssicherung Hessen GQH   (Germany)

Author keywords

Atrial fibrillation; Care delivery; New anticoagulants; Oral anticoagulation; Stroke

Indexed keywords

ATRIAL FIBRILLATION; CLINICAL TRIAL (TOPIC); COMPLICATION; HUMAN; PATHOPHYSIOLOGY; REGISTER; STROKE;

ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HUMANS; REGISTRIES; STROKE;

EID: 84932166617     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/s13104-015-1237-2     Document Type: Article

References (25)

1. Miller KD, Rahman ZU, Sledge GW Jr (2001) Selection bias in clinical trials. Breast Dis 14:31-40
2. EAFT (European Atrial Fibrillation Trial) Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255-1262
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
4. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S et al (2010) Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 9:1157-1163
5. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L et al (2012) Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 11:503-511
6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981-992
7. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A et al (2012) Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 11:315-322
8. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY et al (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370:493-503
9. Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M et al (1997) Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 28:1015-1021
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883-891
11. Foerch C, Misselwitz B, Sitzer M, Berger K, Steinmetz H, Neumann-Haefelin T (2005) Difference in recognition of right and left hemispheric stroke. Lancet 366:392-393
12. Stolz E, Hamann GF, Kaps M, Misselwitz B (2011) Regional differences in acute stroke admission and thrombolysis rates in the German federal state of Hesse. Dtsch Arztebl Int 108:607-611
13. Jauss M, Schutz HJ, Tanislav C, Misselwitz B, Rosenow F (2010) Effect of daytime, weekday and year of admission on outcome in acute ischaemic stroke patients treated with thrombolytic therapy. Eur J Neurol 17:555-561
14. Tanislav C, Milde S, Schwartzkopff S, Sieweke N, Kramer HH, Juenemann M et al (2014) Secondary stroke prevention in atrial fibrillation: a challenge in the clinical practice. BMC Neurol 14:195. doi: 10.1186/s12883-014-0195-y.:95-0195
15. Schmidt R, Ropele S, Ferro J, Madureira S, Verdelho A, Petrovic K et al (2010) Diffusion-weighted imaging and cognition in the leukoariosis and disability in the elderly study. Stroke 41:e402-e408
16. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N (2000) Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 320:1236-1239
17. Darkow T, Vanderplas AM, Lew KH, Kim J, Hauch O (2005) Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin 21:1583-1594
18. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS et al (2004) Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 141:745-752
19. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115:2689-2696
20. Jeerakathil T, Wolf PA, Beiser A, Hald JK, Au R, Kase CS et al (2004) Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. Stroke 35:1831-1835
21. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806-817
22. Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY et al (2012) Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 11:225-231
23. Palm F, Kleemann T, Dos SM, Urbanek C, Buggle F, Safer A et al (2012) Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study) CHADS(2), CHA(2) DS(2)-VASc score, underuse of oral anticoagulation, and implications for preventive measures. Eur J Neurol 20:117-123
24. Giralt-Steinhauer E, Cuadrado-Godia E, Ois A, Jimenez-Conde J, Rodriguez-Campello A, Soriano C et al (2013) Comparison between CHADS2 and CHA2 DS2-VASc score in a stroke cohort with atrial fibrillation. Eur J Neurol 20:623-628
25. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115:2689-2696